PRECISION BIOSCIENCES INC — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precision BioSciences announced first patient dosing in August 2026 in the Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo gene-editing therapy for Duchenne muscular dystrophy. The trial targets ambulatory DMD patients aged 2–7 with exons 45–55 mutations (affecting ~60% of DMD patients); first site was Arkansas Children's Hospital. Initial safety data expected by year-end 2026. No financial figures, partnership amounts, or share issuances disclosed in this filing.
Why this rating
Phase 1/2 dosing milestone is material for a $47.1M clinical-stage biotech; first-in-human data in rare orphan indication with FDA Fast Track and PRV eligibility represents meaningful clinical/regulatory progress, but outcome remains uncertain.
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.